

Title

Meaningful Changes in What Matters to Individuals with Vitiligo: Content Validity and Meaningful Change Thresholds of the Vitiligo Area Scoring Index (VASI)

Authors/Affiliations

Helen Kitchen¹, Kathleen W. Wyrwich^{2‡}, Chloe Carmichael¹, Linda S. Deal², Tatjana Lukic², Tamara Al-Zubeidi¹, Chris Marshall¹, Hannah Pegram^{1‡}, Iltefat H. Hamzavi³, Brett King⁴

1 Clinical Outcomes Assessment, Clarivate, UK

2 Pfizer Inc, NYC, NY, US

3 Henry Ford Medical Centre, US

4 Yale Dermatology, Middlebury, US

[‡]Affiliation when this study was conducted.

Dr King and Dr Hamzavi contributed equally to the senior authorship of this paper

Corresponding author


Helen Kitchen, Clarivate


Helen.kitchen@clarivate.com



Supplementary material

Supplementary material 1. Schematic of Research Process





Abbreviations: F-VASI, Facial Vitiligo Area Scoring Index; T-VASI, Total body Vitiligo Area Scoring Index

Key: Purple font reflects outputs from the research process; black font reflects the methodological steps undertaken to achieve the outputs.



Supplementary material 2. Sampling quotas

Representation of FST 1-6

Sex (>25% male; >25% female)

Education level (~35% high school only, with or without diploma)

1st or 2nd generation living in the US from the Middle East (e.g. Egypt, Iran, Israel, Iraq, Qatar, Syria), Asia (e.g. China, India, Pakistan, Thailand, Indonesia) or Africa (e.g. Nigeria, Ethiopia) (~15% of total sample

Low level of facial vitiligo (n≤10 patients with 0.25-0.50 BSA)

Improved vitiligo within 12 months ($n\geq 10$)



Supplementary material 3. Additional demographic and clinical sample characteristics Adults Adolescents TOTAL									
Demographic characteristic	(N=48)	(N=12)	(N=60)						
	n (%)	n (%)	n (%)						
Self-reported demographic characteristics (N=60)									
Work status									
Working paid	34 (71%)	1 (8%)	35 (58%)						
Student	3 (6%)	12 (100%)	15 (25%)						
Homemaker	4 (8%)	-	4 (7%)						
Other	6 (13%)	-	6 (10%)						
Retired	1 (2%)	-	1 (2%)						
Self-reported improvement in									
vitiligo in past 12 months									
No	40 (83%)	7 (58%)	47 (78%)						
Yes	8 (17%)	4 (33%)	12 (20%)						
Don't know	-	1 (8%)	1 (2%)						
Clin	ician-reported clinical c	haracteristics (N=60)							
	Disease activit	y (Face)							
New/extending lesion(s) in the	29 (60%)	9 (75%)	38 (63%)						
past 3 months		5 (7 5 7 6)							
Confetti-like lesion(s)	8 (17%)	-	8 (13%)						
Trichrome lesion(s)	7 (15%)	-	7 (12%)						
Koebner phenomenon/	2 (4%)	-	2 (3%)						
phenomena									
Coexistence of halo nevus/nevi	1 (2%)	-	1 (2%)						
Unable to say based on	10 (21%)	2 (17%)	12 (20%)						
patient's clinic records [†]									
Now (ovtending locion(s) in the	Disease activity	y (Body)							
New/extending lesion(s) in the past 3 months	31 (65%)	8 (67%)	39 (65%)						
Confetti-like lesion(s)	7 (15%)		7 (12%)						
Trichrome lesion(s)	7 (15%)	-							
Koebner phenomenon/	7 (1570)	_	7 (12%)						
phenomena	1 (2%)	-	1 (2%)						
Coexistence of halo nevus/nevi	2 (4%)	-	2 (3%)						
Unable to say based on									
patient's clinic records [†]	7 (15%)	3 (25%)	10 (17%)						
Comorbidities (selected from a									
pre-defined list)									
Anxiety	16 (33%)	6 (50%)	22 (37%)						
Thyroid disease	9 (19%)	2 (17%)	11 (18%)						
Depression	8 (17%)	1 (8%)	9 (15%)						
ADHD	1 (2%)	4 (33%)	5 (8%)						
Diabetes – Type 1	4 (8%)	1 (8%)	5 (8%)						
Arthritis	5 (10%)	-	5 (8%)						
Asthma	2 (4%)	2 (17%)	4 (7%)						
Alopecia areata	3 (6%)	1 (8%)	4 (7%)						
Rheumatoid arthritis	3 (6%)	-	3 (5%)						
IBD	3 (6%)	-	3 (5%)						
Cardiovascular disease	3 (6%)	-	3 (5%)						
Cancer (excluding skin cancers)	2 (4%)	-	2 (3%)						
Other [‡]	4 (8%)		4 (7%)						

Supplementary material 3. Additional demographic and clinical sample characteristics



-	Adults	Adolescents	TOTAL
Demographic characteristic	(N=48)	(N=12)	(N=60)
	n (%)	n (%)	n (%)
Current treatment(s)*			
Tacrolimus	5 (10%)	3 (25%)	8 (13%)
Phototherapy/NBUVB	3 (6%)	2 (17%)	5 (8%)
Sunscreen	2 (4%)	1 (8%)	3 (5%)
Pimecrolimus	2 (4%)		2 (3%)
Meclizine	2 (4%)	-	2 (3%)
Other [§]	5 (10%)	1 (8%)	6 (10%)
No current treatment(s)	32 (67%)	6 (50%)	38 (63%)
reported	02 (0770)	0 (0070)	00 (00/0)
Previous treatment (s)*			
Steroids/topical creams	8 (17%)	6 (50%)	14 (23%)
Phototherapy/NBUVB	9 (19%)	2 (17%)	11 (18%)
Pimecrolimis	3 (4%)	3 (25%)	6 (10%)
Laser therapy	4 (8%)	1 (8%)	5 (8%)
Clobetasol	4 (8%)	-	4 (7%)
Tacrolimus	4 (8%)	-	4 (7%)
Other [¶]	4 (8%)	1 (8%)	5 (8%)
No previous treatments	19 (40%)	2 (17%)	21 (35%)
reported			
Discontinuation reason*	n=24	n=7	n=31
Ineffective	19 (79%)	6 (86%)	25 (81%)
Cost	2 (8%)	-	2 (6%)
Switched to alternative	2 (8%)	-	2 (6%)
Other ⁺⁺	3 (13%)	1 (14%)	4 (13%)

[†]Clinicians could select this option in instances where they could not see the individual in-person due to the COVID-19 pandemic; ^{*} Multiple treatments (and reasons for discontinuation) may have been reported for each patient. [‡] Other comorbidities included type 2 diabetes, skin cancer, chronic kidney disease, epilepsy, multiple sclerosis, Sjogren syndrome and chronic obstructive pulmonary disease (each reported by N=1; multiple comorbidities may have been reported for each patient).

[§] Other current treatments included triamcinolone (n=2), clobetasol, desonide, hydrocortisone, tofacitinib, crisaborole, an unspecified topical steroid and Excimer laser treatment (each reported by N=1; multiple treatments may have been reported for each patient).

¹ Other previous treatments included liquid nitrogen, triamcinolone, Medclizine, supplements (including vitamins C, B12 and folic acid), pUVA and "tanning" (each reported by N=1; multiple treatments may have been reported for each patient). ⁺⁺ Other reasons for treatment discontinuation included the result being achieved, the treatment being too strong for the face, Covid and "location" (each reported by N=1).



Threshold	Subgroup (Number of patients asked)	Treatment success	Somewhat successful	Not a success	Other response/ Not asked
F-VASI					
F-VASI 50	Adults (n=48)	28 (58%)	2 (4%)	12 (25%)	6 (13%)
	Adolescents (n=11)	11 (100%)	-	-	-
F-VASI 75	Adults (n=48)	39 (81%)	6 (13%)	3 (6%)	-
	Adolescents (n=11)	11 (100%)	-	-	-
F-VASI 90	Adults (n=48)	47 (98%)	-	1 (2%)	-
	Adolescents (n=11)	11 (100%)	-	-	-
T-VASI					
T-VASI 33	Adults (n=40)	21 (53%)	5 (13%)	10 (25%)	4 (10%)
	Adolescents (n=10)	9 (90%)	-	1 (10%)	-
T-VASI 50	Adults (n=38)	30 (79%)	2 (5%)	5 (13%)	1 (3%)
	Adolescents (n=10)	10 (100%)	-	-	-
T-VASI 75	Adults (n=38)	35 (92%)	1 (3%)	2 (5%)	-
	Adolescents (n=10)	10 (100%)	-	-	-

Supplementary material 4. Patient sub-group comparisons of F-VASI and T-VASI thresholds